02.05.26 -- At JP Morgan 2026, Few Showed Up For U.S. Manufacturing

Discover how whether you’re trying to achieve speed and cost-effectiveness or higher yields and glycosylation capabilities, the right system can be tailored to meet the needs of each unique biologic.

USP’s new elastomeric packaging standards shift testing to full system‑level evaluation, strengthen integrity and usability expectations, and place compliance responsibility on drug developers.

To keep pace with surging GLP-1 demand, pharma needs partners that can rapidly scale injectable production while maintaining flexibility, quality, and regulatory rigor.

Antibody-drug conjugate manufacturing includes extremely dangerous ingredients, and most legacy facilities lack the features and flows for safe handling.

Learn actionable strategies that can lead to higher success rates and smarter resource investment, paving the way for a successful path to IND submissions and commercialization.

Gain insights that can support your next steps, whether advancing to a new clinical phase, constructing a new facility, or fine-tuning an existing process to keep pace with market shifts.

Identify potential product failure points and design robust formulations and processes for lyophilized products backed by solid data.

Overcome risks in mAb-SiRNA conjugation, including disulfide scrambling and SiRNA deconjugation, by using advanced chemical and operational solutions to improve material yield and stability.

Learn how biomanufacturing benefits from integrating AI and mechanistic models into early design, allowing developers to overcome productivity limits and accelerate timelines for complex therapeutics.

KinetiSol enhances bioavailability of poorly soluble drugs like Vemurafenib by producing dense amorphous dispersions, outperforming traditional MBP methods in pharmacokinetics and dissolution.

Combining rigorous target validation, early toxicity and pharmacokinetic (PK) testing, and an iterative design process is crucial for identifying viable drug candidates early.

Uncover how a CDMO with extensive experience in protein variant characterization, CQA analytics, and patient-centric product development can ensure the safety and efficacy of your biotherapeutic.

Assimilate how our proven expertise and simplified execution with development, filling, and analytical under one roof ensure safe, efficacious products reach patients in need.

This passive needle guard for pre-filled ISO standard glass syringes is designed to support viscous drug delivery with ergonomics and drug visibility.

Viral clearance protects patients by validating virus removal and inactivation in biologics manufacturing, meeting global standards through rigorous, audit-ready studies and expert oversight.

A strategic alliance accelerates the delivery of complex bioconjugates by integrating the entire drug substance and drug product manufacturing process into one streamlined solution.

Examine how a new high-speed aseptic filling line can help bring your product to market with speed and efficiency while ensuring safety and high product quality.